Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	275.71M
Revenue (ttm)	182.02M
Net Income (ttm)	-10.93M
Shares Out	58.29M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	387,996
Open	4.930
Previous Close	4.910
Day's Range	4.730 - 4.930
52-Week Range	3.300 - 6.750
Beta	0.77
Analysts	Buy
Price Target	13.00 (+174.84%)
Earnings Date	Nov 6, 2024

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 203
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA
• Website: https://www.vandapharma.com

Financial Performance

In 2023, Vanda Pharmaceuticals's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.

Analyst Forecast

According to one analyst, the rating for VNDA stock is "Buy" and the 12-month stock price forecast is $13.0.

Price Target

$13.0

(174.84% upside)

Analyst Consensus: Buy